THAIFEX – HOREC Asia Puts Skills and Execution at the Centre of Hospitality

by | PRNewswire Asia

Live environments and skills programmes addressing day-to-day hospitality and foodservice operations BANGKOK, Jan. 30, 2026 /PRNewswire/ — THAIFEX – HOREC Asia 2026 returns for its third edition from 11 – 13 March 2026 at IMPACT, Muang Thong Thani,...

Envision Energy Partners with REE Group to Deliver Southeast Asia's Largest Single-Turbine Nearshore Wind Projects

by | PRNewswire Asia

HO CHI MINH CITY, Vietnam, Jan. 30, 2026 /PRNewswire/ — Envision Energy, a global leader in green technology, has signed a turbine supply contract with Vietnam’s REE Group for a whole 128MW nearshore wind projects in Vinh Long Province, which...

Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort

by | PRNewswire Asia

PHUKET, Thailand, Jan. 30, 2026 /PRNewswire/ — Recognized as the Top 3 in "Thailand’s Best Family Resorts" by readers of Holidays with Kids magazine, Phuket Marriott Resort & Spa, Merlin Beach solidifies its status as the ultimate family...

NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization

by | PRNewswire Asia

SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company’s novel fast resorbable microsphere for musculoskeletal...

Nature Foods Launches "Contributing to a Full-Flavored Tet": When the Family Meal Becomes a Mission Connecting Generations

by | PRNewswire Asia

HO CHI MINH CITY, Vietnam, Jan. 29, 2026 /PRNewswire/ — Each family has its own Tet meal. Some are abundant, others simple. Yet they all share one common meaning: the family meal is a symbol of sharing, togetherness, and nurturing family bonds. Nature Foods...

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

by | PRNewswire Asia

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study –  The exceptional efficacy of denifanstat (ASC40) observed in the Company’s...